Post date
22/03/2018
Proximus and VIVES II, existing shareholders of Tessares, are thereby strengthening their participation and are joined by the SRIW which is also participating. The amount raised is aimed at speeding
Post date
05/02/2018
- Syndesi Therapeutics to leverage UCB’s expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism
- Series A financing of €17 M
Post date
26/06/2017
Louvain-la-Neuve, 26th June 2017 - Aphea.Bio, spin-off of the VIB, UGent and KU Leuven, will develop sustainable agricultural products based on nature-based microorganisms to increase crop yield and